|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| US State Market Index: Coagulation products |
|
|
|
|
€ 475,00 |
Editeur
: |
BizMiner |
Langue
: |
Anglais |
Date de publication : |
Juillet 2006 |
Taille du document : |
12 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pain Therapeutics: A Strategic Re-evaluation.
198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused |
955,00 €
|
| |
| |
Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environment
148 pages | |
Obesity Drug Markets in the US and EUAnalysis of product pipelines and competitive environmentBusiness Intelligence for the Pharmaceutical IndustryBusiness Insights' portfolio of healthcare management |
3 068,00 €
|
| |
| |
Regulatory Affairs: Paths to Approval
113 pages | Février 1999 |
Area Specific Chapters : The regulatory systems governing clinical trials and drug approvals are examined for the US, Europe, and Australia, Canada and Japan, including analysis of the implicatio |
795,00 €
|
| |
| |
MarketWatch: Biotechnology
32 pages | |
Datamonitor's Biotechnology MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the Biotechnology industry.
The report contains th |
160,00 €
|
| |
| |
Commercial and Pipeline Insight: Fibromyalgia - Approvals legitimize condition and expose underserved patient population
193 pages | |
IntroductionWith a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies.
Estimated to total |
12 160,00 €
|
| |
| |
Commercial and Pipeline Insight: Vaccines for Adults and the Elderly - New blockbuster opportunities ahead
161 pages | |
IntroductionVaccines have re-emerged as successful revenue generators for Big Pharma, with adults and the elderly now increasingly coming into focus as the next big opportunity in this sector.
An a |
12 320,00 €
|
| |
| |
Top Ten and Emerging Pharmaceutical markets
214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals.
Mar |
795,00 €
|
| |
| |
The Pharmaceutical Outsourcing Outlook 1998-2003
199 pages | Juin 1999 |
The streamlining of pharmaceutical companies that has taken place in recent years has allowed them to focus resources and investment on core specialities.
This, in turn, has led to a greater re |
795,00 €
|
| |
| |
Healthcare In Scotland
52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E |
327,00 €
|
| |
| |
Global Pharmaceutical: a market, company and disease analysis
150 pages | Octobre 1998 |
What will drive pharmaceutical market growth into the 21st Century? What are the key challenges facing pharmaceutical manufacturers? Who are the market leaders in each sector? What strategies ar |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| US State Market Index: Coagulation products |
|
|
The metrics in this report cover three year trends in Coagulation products [Manufacturing sector], broken out on a state-by-state basis. Analysis is based on data applied from 2 industry firms. Industry market vitality measures for each state are benchmarked against US averages for the industry, creating easy comparison of state-by-state performance. Industry sales are detailed for both company-wide headquarters data and locally generated sales levels. The report also compares proprietary measures in each state and the US, including failure rates, entrepreneurial activity and new branch development rates in the industry.
|
|
State Market Index Contents
P1-3 Introduction and context for the measures
P4:Industry population and segmentation
P5:Establishment,company and branch failure rates
P6:Total industry sales volume (reported and locally generated)
P7:Average annual reported sales
P8:Average annual generated sales
P9:Startup activity, new branch development,employment concentration
P10:Overall Index
P11:About the data
|
|
|
PPLSEN
|
|
|
|
|
